



IKARIA® ANNOUNCES ELECTION OF HOWARD H. PIEN TO BOARD OF DIRECTORS

Clinton, NJ, April 14, 2010 – Ikaria Holdings, Inc. today announced that Howard H. Pien has been elected as an independent member of the company's board of directors. Mr. Pien, who has more than 25 years of international management experience in the biopharmaceutical sector, also will become a member of Ikaria's compensation committee. Most recently, he was president, CEO and chairman of Medarex, Inc., which was acquired by Bristol-Myers Squibb in 2009.

Mr. Pien currently serves as a director of several companies, including ViroPharma, Inc. and Immunogen. He also is an advisor to Warburg Pincus. Previously, he was president, CEO and chairman of Chiron Corporation, until its acquisition by Novartis in 2006. Mr. Pien also has held senior management positions at GlaxoSmithKline and its predecessor SmithKline Beecham, including the positions of president of its U.S. pharmaceuticals business and president of its international operations.

"We are very pleased that Howard has joined Ikaria's board of directors," said Daniel Tass, chairman and CEO, Ikaria. "Howard's experience in running successful pharmaceutical businesses -- by developing market-leading products, leading successful commercial operations, and developing strategic partnerships -- will be extremely valuable in helping Ikaria as it grows."

Mr. Pien also has been involved in a number of non-profit and industry organizations, and holds directorship on the Children's Hospital & Research Center in Oakland, CA, the California Healthcare Institute, the Biotechnology Industry Association (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Pien holds a BS from the Massachusetts Institute of Technology and an MBA from Carnegie-Mellon University.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the needs of critically ill patients. The company's lead product, INOMAX® (nitric oxide) for inhalation, is approved for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America, Australia, Japan and Mexico. Ikaria acquired the North American and Australian rights to terlipressin, a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide licenses to a potential treatment for preventing pathological cardiac remodeling following acute myocardial infarction, and to a portfolio of investigational compounds focused on vascular leakage for a range of critical care conditions, such as acute lung and kidney injury. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.

###